Forth Marc 4

Accession 0001104659-23-083566

CIK 0001837607other

View on SEC.gov Company Profile

Filed

Jul 23, 8:00 PM ET

Accepted

Jul 24, 9:07 PM ET

Size

19.9 KB

Accession

0001104659-23-083566

Insider Transaction Report

Form 4

Period: 2023-07-21

AEON Biopharma, Inc.AEON

Forth Marc

Director

Transactions

Award
Stock Option
2023-07-21+291,332→ 291,332 total
Exercise: $10.00Exp: 2031-09-09→ Common Stock (291,332 underlying)
Award
Stock Option
2023-07-21+381,480→ 381,480 total
Exercise: $10.00Exp: 2032-03-09→ Common Stock (381,480 underlying)
Award
Stock Option
2023-07-21+324,021→ 324,021 total
Exercise: $10.00Exp: 2030-08-05→ Common Stock (324,021 underlying)
Award
Stock Option
2023-07-21+970,588→ 970,588 total
Exercise: $10.00Exp: 2029-11-20→ Common Stock (970,588 underlying)
Award
Stock Option
2023-07-21+194,118→ 194,118 total
Exercise: $10.00Exp: 2032-03-09→ Common Stock (194,118 underlying)
Award
Restricted Stock Units
2023-07-21+279,855→ 279,855 total
→ Common Stock (279,855 underlying)

Footnotes (9)

[F1]On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.
[F2]At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
[F3]Represents an award of stock options on November 20, 2019, which vests in four yearly installments from June 11, 2019, subject to the reporting person's continued service through the applicable vesting date.
[F4]Represents an award of stock options on August 5, 2020, which vests in four yearly installments from July 1, 2020, subject to the reporting person's continued service through the applicable vesting date.
[F5]Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date.
[F6]Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.
[F7]Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.
[F8]At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
[F9]Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.

Documents

1 file

4
tm2321918-9_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

AEON Biopharma, Inc.

CIK 0001837607

→

Entity typeother

Related Parties

filerCIK 0001816988

Filing Metadata

Form type: 4
Filed: Jul 23, 8:00 PM ET
Accepted: Jul 24, 9:07 PM ET
Size: 19.9 KB

View on SEC.gov